Late urinary toxicity after prostate intensity-modulated radiation therapy for patients with history of invasive interventions for prostate or bladder.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
32 patients with prostate cancer and a history of invasive interventions for the prostate or bladder were retrospectively analyzed.
I · Intervention 중재 / 시술
moderately hypo-fractionated IMRT with a median dose of 54 Gy in 15 fractions
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Clinical outcomes of IMRT in 32 patients with prostate cancer and a history of invasive interventions for the prostate or bladder were retrospectively analyzed. Although the incidence of late genitourinary toxicities was relatively high, prostate IMRT was considered a safe and feasible treatment option for such a population.
[PURPOSE] The aim of this study was to evaluate late genitourinary (GU) toxicities on receiving intensity-modulated radiation therapy (IMRT) in patients with prostate cancer (PCa) who had a history of
- 추적기간 77.3 months
APA
Kato K, Aizawa R, et al. (2026). Late urinary toxicity after prostate intensity-modulated radiation therapy for patients with history of invasive interventions for prostate or bladder.. Japanese journal of radiology. https://doi.org/10.1007/s11604-026-01969-9
MLA
Kato K, et al.. "Late urinary toxicity after prostate intensity-modulated radiation therapy for patients with history of invasive interventions for prostate or bladder.." Japanese journal of radiology, 2026.
PMID
41831200
Abstract
[PURPOSE] The aim of this study was to evaluate late genitourinary (GU) toxicities on receiving intensity-modulated radiation therapy (IMRT) in patients with prostate cancer (PCa) who had a history of invasive interventions for the prostate or bladder.
[MATERIALS AND METHODS] Among patients who received IMRT for PCa at our institution between August 2000 and December 2022, clinical outcomes among those with a history of invasive interventions for the prostate or bladder were retrospectively analyzed. Cumulative incidence rates of late ≥ grade 2 and ≥ grade 3 GU and gastrointestinal toxicities, and rates of overall survival (OS) and biochemical failure-free survival (BFFS) were evaluated.
[RESULTS] A total of 32 consecutive patients were analyzed, among whom 28 received conventional fractionated IMRT with a median dose of 74 Gy in 37 fractions, and 4 underwent moderately hypo-fractionated IMRT with a median dose of 54 Gy in 15 fractions. The median follow-up period was 77.3 months after IMRT. Cumulative incidence rates of ≥ grade 2 and ≥ grade 3 GU toxicities were 20.7 and 4.3% at 5 years, and 26.4 and 4.3% at 8 years, respectively. More than 10 years after IMRT, 18.8% of patients developed ≥ grade 2 GU toxicities. OS and BFFS rates were 89.5 and 76.0% at 5 years, and 89.5 and 60.7% at 8 years, respectively.
[CONCLUSION] Prostate IMRT for patients with a history of invasive interventions for the prostate or bladder was considered a safe and feasible treatment option, although the incidence of late GU toxicities was relatively high. Long-term follow-up with close attention to the detection of GU toxicities is recommended for such a population. Clinical outcomes of IMRT in 32 patients with prostate cancer and a history of invasive interventions for the prostate or bladder were retrospectively analyzed. Although the incidence of late genitourinary toxicities was relatively high, prostate IMRT was considered a safe and feasible treatment option for such a population.
[MATERIALS AND METHODS] Among patients who received IMRT for PCa at our institution between August 2000 and December 2022, clinical outcomes among those with a history of invasive interventions for the prostate or bladder were retrospectively analyzed. Cumulative incidence rates of late ≥ grade 2 and ≥ grade 3 GU and gastrointestinal toxicities, and rates of overall survival (OS) and biochemical failure-free survival (BFFS) were evaluated.
[RESULTS] A total of 32 consecutive patients were analyzed, among whom 28 received conventional fractionated IMRT with a median dose of 74 Gy in 37 fractions, and 4 underwent moderately hypo-fractionated IMRT with a median dose of 54 Gy in 15 fractions. The median follow-up period was 77.3 months after IMRT. Cumulative incidence rates of ≥ grade 2 and ≥ grade 3 GU toxicities were 20.7 and 4.3% at 5 years, and 26.4 and 4.3% at 8 years, respectively. More than 10 years after IMRT, 18.8% of patients developed ≥ grade 2 GU toxicities. OS and BFFS rates were 89.5 and 76.0% at 5 years, and 89.5 and 60.7% at 8 years, respectively.
[CONCLUSION] Prostate IMRT for patients with a history of invasive interventions for the prostate or bladder was considered a safe and feasible treatment option, although the incidence of late GU toxicities was relatively high. Long-term follow-up with close attention to the detection of GU toxicities is recommended for such a population. Clinical outcomes of IMRT in 32 patients with prostate cancer and a history of invasive interventions for the prostate or bladder were retrospectively analyzed. Although the incidence of late genitourinary toxicities was relatively high, prostate IMRT was considered a safe and feasible treatment option for such a population.
같은 제1저자의 인용 많은 논문 (5)
- Efficacy of Fusion Imaging and Cone-Beam Computed Tomography-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Poorly Visualized on Ultrasonography.
- Establishment and characterization of a novel cell line ICH-BCPALL-3 from B cell precursor acute lymphoblastic leukemia with TCF3::HLF.
- [A Case of Anaplastic Carcinoma of the Pancreas with Long-Term Prognosis by Multidisciplinary Treatment].
- [EARLY OUTCOMES OF REFRACTORY OVERACTIVE BLADDER TREATED WITH BOTULINUM TOXIN IN A FEMALE UROLOGY CLINIC].
- Successful perioperative management of a patient with primary systemic carnitine deficiency: a case report.